8-K: Horizon Space II Adds Directors, Updates Ownership for SL Bio Merger

Horizon Space Acquisition II Corp. announced additional independent director nominees and updated beneficial ownership details for its upcoming business combination with SL BIO Ltd.

Summary

• Horizon Space Acquisition II Corp. (HSPT) filed a definitive proxy statement on January 13, 2026, for a Business Combination Meeting on February 12, 2026, concerning its proposed merger with SL BIO Ltd.
• Two new independent director nominees, Joseph Levinson and Qian (Hebe) Xu, will be added to the combined entity, SL Science Holding Limited (PubCo), following the Business Combination.
• Joseph Levinson brings over 25 years of experience in managing cross-border issues for U.S.-listed foreign companies and accounting, holding a United States Certified Public Accountant license.
• Qian (Hebe) Xu has more than 15 years of experience in financial markets, specializing in US-China cross-border transactions, and currently serves as an independent director for HSPT and Hongli Group Inc.
• Neither Joseph Levinson nor Qian (Hebe) Xu will serve as a member of PubCo's board committees.
• The beneficial ownership table for PubCo Ordinary Shares immediately following the Business Combination has been updated.
• In the no redemption scenario, 566,591,350 PubCo Ordinary Shares are expected to be issued and outstanding.
• In the maximum redemption scenario, 559,956,923 PubCo Ordinary Shares are expected to be issued and outstanding.
• William Wang, through SL Link Holding Ltd. and SL Link Co., Ltd., will beneficially own 333,832,129 PubCo Ordinary Shares, representing 58.9% of voting power in the no redemption scenario and 59.6% in the maximum redemption scenario.
• Qian (Hebe) Xu will beneficially own 20,000 PubCo Ordinary Shares (converted from HSPT founder shares), representing less than 1% of voting power.
• All director nominees and executive officers as a group will beneficially own 333,852,129 PubCo Ordinary Shares, representing 58.9% of voting power in the no redemption scenario and 59.6% in the maximum redemption scenario.
• There are no changes to the Business Combination Meeting time (9:00 a.m. Eastern Time, February 12, 2026), redemption deadline (5:00 p.m. Eastern Time, February 10, 2026), location, record date (December 29, 2025), purpose, or any of the proposals.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, as the addition of experienced independent directors strengthens corporate governance for the upcoming business combination, which is proceeding as scheduled.

Positives

• The addition of two experienced independent directors, Joseph Levinson (accounting, public company experience) and Qian (Hebe) Xu (financial markets, US-China cross-border transactions), enhances corporate governance and expertise for the combined entity.
• The business combination meeting schedule remains unchanged, indicating the merger process is proceeding as previously outlined and on track.

Risks

• SL Bio's or the combined company's limited operating history.
• The ability of SL Bio or the combined company to identify and integrate acquisitions.
• General economic and market conditions impacting demand for the products of SL Bio or the combined company.
• The inability to complete the proposed Business Combination.
• The inability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, the amount of cash available following any redemptions by HSPT's shareholders.
• The ability to meet stock exchange listing standards following the consummation of the proposed Business Combination.
• Costs related to the proposed Business Combination.
• The possibility that the proposed Business Combination does not close, including due to the failure to receive required security holder approvals, or the failure of other closing conditions.

Future Outlook

The combined company (PubCo) expects its executive compensation program to reflect SL Bio's compensation policies and philosophies, which may be modified and updated over time. Decisions regarding executive officer compensation will be made by PubCo's compensation committee. Non-executive independent directors are expected to receive compensation commensurate with their duties and experience, including annual or monthly cash retainers, reimbursement of reasonable expenses, and potentially equity-based awards under an equity compensation plan to be adopted after the Business Combination.

Management Comments

• PubCo expects its executive compensation program to reflect SL Bio's compensation policies and philosophies, as they may be modified and updated from time to time.
• PubCo expects that decisions with respect to the compensation of its executive officers, including the named executive officers, will be made by the compensation committee of PubCo's board of directors.
• PubCo's non-executive independent directors will be entitled to compensations commensurate with their respective duties and experience, including annual or monthly cash retainer, reimbursement of reasonable expenses incurred in relation to the performance of their duties, and, with respect to certain independent directors, equity-based awards pursuant to an equity compensation plan to be adopted following the consummation of the Business Combination.

Industry Context

StockSavvy.ai notes that the addition of experienced independent directors, particularly those with cross-border and financial market expertise, is a common practice in SPAC mergers to bolster corporate governance and investor confidence ahead of a de-SPAC transaction. The focus on US-China cross-border transactions for Ms. Xu suggests a strategic emphasis on international markets or investor relations for the combined entity.

Comparison to Industry Standards

• The appointment of independent directors with strong financial and accounting backgrounds, such as Joseph Levinson (a Certified Public Accountant), aligns with best practices for public companies, similar to board compositions seen in established Nasdaq-listed firms in sectors like biotechnology or technology, where robust financial oversight is critical.
• The inclusion of a director with extensive US-China cross-border transaction experience, Qian (Hebe) Xu, is particularly relevant for companies with international operations or investor bases, mirroring strategies employed by companies like Alibaba (NYSE: BABA) or Baidu (NASDAQ: BIDU) which navigate complex global financial landscapes.
• The beneficial ownership structure, where a significant portion (58.9%-59.6%) is concentrated with the CEO (William Wang) through holding companies, is not uncommon in founder-led or private equity-backed companies going public. However, it warrants close monitoring by investors for potential governance implications, similar to structures observed in companies like Tesla (NASDAQ: TSLA) with Elon Musk's substantial stake or Meta Platforms (NASDAQ: META) with Mark Zuckerberg's control.

Management Changes

Corporate Governance

Related Party Transactions

• SL Link Co., Ltd., a company controlled by William Wang (who will be the Chief Executive Officer, Director, and Chairman of Board of PubCo), purchased 30,000 ordinary shares of SL Bio from an individual shareholder on January 5, 2026, at a purchase price of US$66.67 per share.
• William Wang's equity interest in PubCo will be beneficially owned through SL Link Holding Ltd. (owned equally by Mr. Wang and his spouse) and SL Link Co., Ltd.

Stakeholder Impact

• Shareholders: Will vote on the business combination; updated beneficial ownership information provides clarity on post-merger control; the addition of experienced independent directors may improve governance and oversight.
• Management/Directors: New independent directors appointed to the future board; compensation policies for executive officers and independent directors outlined for the combined entity.
• Investment Professionals: Provides updated information on corporate governance and ownership structure for the pending business combination, aiding in valuation and risk assessment.

Next Steps

• HSPT shareholders will vote on the proposed business combination at the Business Combination Meeting on February 12, 2026.
• Following the consummation of the Business Combination, an equity compensation plan is expected to be adopted for independent directors.
• Decisions regarding executive compensation for PubCo will be made by its compensation committee after the Business Combination.

Key Dates

Recommendation

The filing provides procedural updates regarding the ongoing business combination, including new independent director nominees and updated beneficial ownership. While the addition of experienced directors is a positive for governance, the core financial and operational details of the combined entity are not significantly altered or revealed in this 8-K. Investors should hold and await the outcome of the Business Combination Meeting and further disclosures regarding the combined entity's strategy and financial performance before making a more definitive investment decision.

Keywords

SPAC, Business Combination, Merger, SL BIO, Horizon Space Acquisition II, HSPT, Director Nominees, Corporate Governance, SEC Filing, 8-K, De-SPAC, Public Company, Nasdaq